| Identification | Back Directory | [Name]
2H-Indol-2-one, 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-5-methoxy- | [CAS]
854171-31-6 | [Synonyms]
A3334
2H-Indol-2-one, 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-5-methoxy- | [Molecular Formula]
C17H13N3O3 | [MOL File]
854171-31-6.mol | [Molecular Weight]
307.3 |
| Chemical Properties | Back Directory | [Boiling point ]
566.9±50.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
8.56±0.20(Predicted) | [color ]
Brown to reddish brown | [Cosmetics Ingredients Functions]
SKIN PROTECTING
SKIN CONDITIONING - MISCELLANEOUS
HAIR CONDITIONING |
| Hazard Information | Back Directory | [Uses]
A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH[1]. | [in vivo]
A3334 (25 mg/kg; p.o. once daily for 16 weeks) has anti-obesity effects in the HFD mice, and has no effect on mice fed with normal diet[1].
A3334 (25 mg/kg; p.o. once daily for 5 days) significantly reduces fasting glucose and the levels of glucose tolerance (GTT) and insulin tolerance (ITT) in serum in mice[1].
A3334 (25 mg/kg; p.o. once daily for 3 weeks) significantly abolishes hepatosteatosis and the increased levels of alanine transaminase (ALT) and aspartatetransaminase (AST) in mice[1]. | Animal Model: | Male C57BL/6N mice (6-week-old) are fed on the high fat die (HFD) for 16 weeks[1] | | Dosage: | 25 mg/kg | | Administration: | P.o. daily for 16 weeks | | Result: | Not observed the HFD-induced body weight gain and abdominal obesity.
Reduced the level of triglyceride and total cholesterol and increased the level of HDL-cholesterol.
Suppressed the increase in adipocyte cell sizes and enhancement of inflammation.
|
| [References]
[1] Choi KY, et, al. Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof. WO2020079569. |
|
|